Biotechnology News and Research

RSS

University of Leicester scientists identify unique forms of spinal nerve activity

Scientists from the University of Leicester have hit upon unique forms of spinal nerve activity that shape output of nerve cell networks controlling motor behaviours.

9 Nov 2012

ACT announces results from three ongoing stem cell clinical trials for macular degeneration

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that its upcoming conference call on its third quarter financial results will also provide some representative examples of data being collected from patients in its clinical trials for forms of macular degeneration.

9 Nov 2012

Teleconcussion for diagnosis and management of mild TBI in athletes

Concussion is a common disorder estimated to affect no fewer than 1.7-3.8 million people in the U.S. each year. Many more people with concussion likely do not seek medical care for symptoms of concussion and may suffer long-lasting, progressive, and profoundcognitive, psychiatric, and neurologic effects.

9 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

Positive results from Palatin’s bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

9 Nov 2012

Roundup: Planned Parenthood asks for extended ban on Texas funding cut; Election's effect on Massachusetts health businesses

Planned Parenthood is asking a Texas judge to extend an order blocking the state from cutting funding to its clinics because the organization provides abortion services. Texas officials were blocked by an Oct. 26 temporary restraining order issued by Judge Amy Clark Meachum in Austin from eliminating public funds for the 49 Planned Parenthood clinics in the state that don't provide abortions.

8 Nov 2012

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

Albireo AB, a biopharmaceutical company specializing in gastroenterology, today announced that A4250 (an inhibitor of the ileal bile acid transporter, IBAT/ASBT) has been granted orphan-drug designation by the U.S Food and Drug Administration for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and Primary Biliary Cirrhosis (PBC).

8 Nov 2012

BioCryst completes planned interim analysis of peramivir Phase 3 trial for serious influenza

BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.

8 Nov 2012

Premenopausal use of hormonal contraceptives may improve women’s cognitive abilities

Premenopausal use of hormonal contraceptives may improve the cognitive abilities of women in midlife and for years afterward. This finding may have implications for prevention of declining cognitive function that occurs with advancing age and in diseases such as Alzheimer's.

8 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Ion AmpliSeq Community Panels from Life Technologies

Life Technologies Corporation today announced Ion AmpliSeq Community Panels, a community-driven solution to gene panel sequencing that leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.

7 Nov 2012

Texas Biomed develops rapid, less expensive route to screen suitable tests for bioterror threats

Texas Biomedical Research Institute scientists in San Antonio have developed a faster, less expensive route to screen suitable tests for bioterror threats and accelerate the application of countermeasures.

7 Nov 2012

Treatment with AMG 145 reduces LDL cholesterol

Amgen today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol.

7 Nov 2012

Researchers succeed in teaching computers how to identify commonalities in DNA sequences

Johns Hopkins researchers have succeeded in teaching computers how to identify commonalities in DNA sequences known to regulate gene activity, and to then use those commonalities to predict other regulatory regions throughout the genome. The tool is expected to help scientists better understand disease risk and cell development.

7 Nov 2012

$Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina$

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Cryopraxis/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013.

6 Nov 2012

Comprehensive review article on baroreflex sensitivity after SCI

Spinal cord injury (SCI) can disrupt the body's sensitive signaling mechanisms that control blood pressure, breathing, and oxygen delivery to the heart and other organs during changes in body position. Cardiovascular (CV) disease is a leading cause of illness and death following SCI, and changes in baroreflex sensitivity-the body's ability to detect and respond to changes in blood pressure-may be predictive of a CV event.

6 Nov 2012

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Virttu launches REPLICATE- Open Innovation Forum

Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE- Open Innovation Forum.

6 Nov 2012

Affymetrix reports net loss of $17.9 million for third quarter 2012

Affymetrix, Inc., today reported its operating results for the third quarter of 2012. Total revenue for the quarter was $79.6 million, including approximately $17.6 million in revenue from eBioscience during the third quarter of 2012. This compares to total revenue of $64.0 million for the same period of 2011.

5 Nov 2012

Biotechnology News and Research

University of Leicester scientists identify unique forms of spinal nerve activity

ACT announces results from three ongoing stem cell clinical trials for macular degeneration

Teleconcussion for diagnosis and management of mild TBI in athletes

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Positive results from Palatin’s bremelanotide Phase 2B trial on female sexual dysfunction

Roundup: Planned Parenthood asks for extended ban on Texas funding cut; Election's effect on Massachusetts health businesses

FDA grants Albireo's A4250 orphan-drug designation for treatment of PFIC and PBC

BioCryst completes planned interim analysis of peramivir Phase 3 trial for serious influenza

Premenopausal use of hormonal contraceptives may improve women’s cognitive abilities

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Ion AmpliSeq Community Panels from Life Technologies

Texas Biomed develops rapid, less expensive route to screen suitable tests for bioterror threats

Treatment with AMG 145 reduces LDL cholesterol

Researchers succeed in teaching computers how to identify commonalities in DNA sequences

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Comprehensive review article on baroreflex sensitivity after SCI

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Virttu launches REPLICATE- Open Innovation Forum

Affymetrix reports net loss of $17.9 million for third quarter 2012

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News